HYTN Innovations Inc - HYTNF STOCK NEWS

HYTN Innovations Inc. (HYTN) welcomes the U.S. recommendation to reclassify cannabis from a Schedule I to a Schedule III controlled substance, viewing it as a positive step towards harmonizing federal regulations with global trends. The reclassification is expected to facilitate research, reduce operational complexities, alleviate tax burdens, and enhance the economic environment for cannabis businesses. HYTN sees this as a growth opportunity that could impact the global approach to cannabis regulation and integration into mainstream healthcare and consumer markets.

HYTN Innovations Inc. announces significant advancements in its Good Manufacturing Practice (GMP) stability programs, setting industry benchmarks in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis. The company expands its stability program to include cannabis products in jars and bags, as well as psilocybin-containing mushrooms, showcasing a commitment to product excellence, consumer safety, and innovation. With data support for shelf lives of six months for bagged cannabis products and one year for jarred products, HYTN aims to lead in GMP processing of psilocybin and other derivatives from mushrooms.

HYTN Innovations Inc. welcomed Health Canada's conduct of a Drug Establishment License (DEL) audit to expand its Good Manufacturing Practices (GMP) capabilities. The recent GMP certification for its Kelowna facility by Australia's TGA under the PIC/S standard will enhance HYTN's manufacturing capabilities, allowing for the development and sale of additional compounds and product variations. The Company aims to pursue expanded clinical and commercial opportunities, including IND submissions with the FDA.

HYTN Innovations Inc. achieves GMP certification for its Kelowna production facility, positioning itself as a leader in the cannabis industry. The company plans to transform Canadian-grown cannabis into GMP-certified medical products for international markets, leveraging its regulatory compliance and supply chain capabilities. With a focus on global commercialization, HYTN aims to capitalize on the opening of Germany's medical cannabis market and expand its successful export footprint in Australia.

HYTN Innovations Inc. receives Good Manufacturing Practice (GMP) certification from Australia's TGA for its Kelowna production facility, enabling the production of cannabis medical products for international trade.

HYTN Innovations Inc. successfully completes a Good Manufacturing Practices audit by Australia's TGA, positioning the company to access international medical markets. The GMP certification allows HYTN to package and label cannabis goods in accordance with international standards, fostering collaborations with global firms and expanding commercial opportunities.

HYTN Innovations Inc. expands its Nano Shot Citrus product to British Columbia and Alberta, following success in Ontario. The unique product offers 100 mg of nano-emulsified THC for precise consumption customization. The company aims to meet changing customer needs and increase domestic sales through innovation and quality.

HYTN Innovations Inc. (CSE: HYTN) announced on March 2, 2023, that it has submitted an amendment to its Controlled Drugs and Substances Dealers License with Health Canada. This amendment aims to expand its offerings to include compounds like MDMA, ketamine, LSD, and cocaine, in addition to cannabinoids and psilocybin. The company is also in the review stage for a Drug Establishment License and a Precursors License. This strategic move will enhance HYTN's operational capabilities and solidify its position in the psychoactive compound market.

HYTN is committed to regulatory compliance and aims to provide high-quality controlled substances for clinical trials and special access uses, positioning itself well for future growth.

HYTN Innovations Inc. (HYTN) has announced the successful cultivation of psilocybin mushrooms under a Dealer's License from Health Canada, marking a significant step in their mission to lead in psychoactive compound manufacturing. The company has upgraded its Kelowna facility with advanced analytical equipment to enhance Active Pharmaceutical Ingredient (API) development and is partnering with industry experts to advance its product offerings. HYTN is actively pursuing Current Good Manufacturing Practice (cGMP) certification to ensure quality in psilocybin extracts and cannabis products, with the aim of becoming a top global producer of APIs.